Literature DB >> 18501568

Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro.

Tathagata Dutta1, Minakshi Garg, Narendra K Jain.   

Abstract

HIV infected macrophages are considered as reservoirs for spreading the virus in AIDS patients. Tuftsin not only binds specifically to the mononuclear phagocytic cells but also enhances their natural killer activity. The purpose of this study is to explore the targeting potential and anti-HIV activity of efavirenz (EFV) loaded, tuftsin conjugated 5th generation poly(propyleneimine) dendrimers (TuPPI) in vitro. Tuftsin was chemically conjugated to 5th generation poly(propyleneimine) dendrimers (PPI). The entrapment efficiency of PPI and TuPPI were found to be 37.43+/-0.3% and 49.31+/-0.33%, respectively. TuPPI was found to slow down and prolong the in vitro release of EFV upto 144h against PPI, which releases the drug completely within 24 h. TuPPI possessed negligible cytotoxicity as compared to that of PPI. The cellular uptake of TuPPI was found to be 34.5 times higher than that of the free drug in first 1 h and was significantly higher in HIV infected macrophages than that of uninfected cells. TuPPI was found to reduce the viral load by 99% at a concentration of 0.625 ng/ml, which is due to the enhanced cellular uptake, reduced toxicity and the inherent anti-HIV activity of TuPPI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18501568     DOI: 10.1016/j.ejps.2008.04.002

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  25 in total

1.  Preparation and long-term biodistribution studies of a PAMAM dendrimer G5-Gd-BnDOTA conjugate for lymphatic imaging.

Authors:  Ana Christina Opina; Karen J Wong; Gary L Griffiths; Baris I Turkbey; Marcelino Bernardo; Takahito Nakajima; Hisataka Kobayashi; Peter L Choyke; Olga Vasalatiy
Journal:  Nanomedicine (Lond)       Date:  2014-11-13       Impact factor: 5.307

Review 2.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

Review 3.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

Review 4.  Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.

Authors:  Tewodros Mamo; E Ashley Moseman; Nagesh Kolishetti; Carolina Salvador-Morales; Jinjun Shi; Daniel R Kuritzkes; Robert Langer; Ulrich von Andrian; Omid C Farokhzad
Journal:  Nanomedicine (Lond)       Date:  2010-02       Impact factor: 5.307

Review 5.  Progress in antiretroviral drug delivery using nanotechnology.

Authors:  Rama Mallipeddi; Lisa Cencia Rohan
Journal:  Int J Nanomedicine       Date:  2010-08-09

Review 6.  Nano-ART and NeuroAIDS.

Authors:  Malay K Das; Anupam Sarma; Tapash Chakraborty
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

Review 7.  NanoART, neuroAIDS and CNS drug delivery.

Authors:  Ari Nowacek; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

Review 8.  Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.

Authors:  Madhavan Nair; Rahul Dev Jayant; Ajeet Kaushik; Vidya Sagar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-02       Impact factor: 15.470

9.  Nanoparticle Uptake: The Phagocyte Problem.

Authors:  Heather Herd Gustafson; Dolly Holt-Casper; David W Grainger; Hamidreza Ghandehari
Journal:  Nano Today       Date:  2015-09-05       Impact factor: 20.722

Review 10.  Nanoparticle-based drug delivery to the vagina: a review.

Authors:  Laura M Ensign; Richard Cone; Justin Hanes
Journal:  J Control Release       Date:  2014-05-14       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.